Immune Checkpoint Inhibitors Market (By Drug Type: CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor; By Disease Indication: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, Others; By End-Users: Hospitals, Specialty Clinics, Academic & Research Institutions) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immune Checkpoint Inhibitors Market
5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immune Checkpoint Inhibitors Market, By Drug Type
8.1. Immune Checkpoint Inhibitors Market, by Drug Type, 2023-2032
8.1.1 CTLA-4 Inhibitor
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. PD-1 Inhibitor
8.1.2.1. Market Revenue and Forecast (2021-2032)
8.1.3. PD-L1 Inhibitor
8.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 9. Global Immune Checkpoint Inhibitors Market, By Disease Indication
9.1. Immune Checkpoint Inhibitors Market, by Disease Indication, 2023-2032
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Bladder Cancer
9.1.2.1. Market Revenue and Forecast (2021-2032)
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast (2021-2032)
9.1.4. Hodgkin lymphoma
9.1.4.1. Market Revenue and Forecast (2021-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2032)
Chapter 10. Global Immune Checkpoint Inhibitors Market, By End-Users
10.1. Immune Checkpoint Inhibitors Market, by End-Users, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2021-2032)
10.1.3. Academic & Research Institutions
10.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 11. Global Immune Checkpoint Inhibitors Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.1.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.1.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.1.4.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.1.5.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.2.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.4.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.5.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.6.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.7.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.3.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.4.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.5.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.6.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.7.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.4.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.5.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.6.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.7.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.5.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.5.4.3. Market Revenue and Forecast, by End-Users (2021-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2021-2032)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.5.5.3. Market Revenue and Forecast, by End-Users (2021-2032)
Chapter 12. Company Profiles
12.1. AstraZeneca PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company (ARMO Biosciences.)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Roche Holding AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Incyte Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi, Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA (EMD Serono Inc.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample